Supplementary Table 5 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
Supplementary Table 5. Incidence of adverse events by maximum grade in the safety population.
创建时间：
2023-07-17
